Antiarrhythmic peptides (AAPs) are a group of compounds with antiarrhythmic properties; however, their use has been hampered by very low plasma stability. The aim of this study was to compare the in vitro and in vivo stability of our new stable AAP analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH 2 (ZP123) with the previously described AAP analog AAP10. Moreover, the effect of the two compounds was examined in a murine in vivo model of ouabain-induced second degree AV-block, and the effect on dispersion of action potential duration (APD dispersion) was studied during hypokalemic-ischemia in isolated perfused rabbit hearts. The in vitro t 1/2 of ZP123 in rat and human plasma was about 1,700 times longer than t 1/2 of AAP10. Due to rapid elimination, it was not possible to obtain an in vivo pharmacokinetic characterization of AAP10; however, calculations suggested that the clearance of ZP123 was at least 140 times slower than for AAP10. AAP10 and ZP123 produced a dose-dependent delay in onset of ouabain-induced AV-block in mice at doses of 10 Ϫ11 to 10 Ϫ7 mol/kg i.v. ZP123 and 10 Ϫ11 to 10 Ϫ6 mol/kg i.v. AAP10. Maximal efficacy of ZP123 was reached at a 10-fold lower dose (10 Ϫ8 mol/kg i.v.) than with AAP10. In the isolated rabbit hearts, ZP123 and AAP10 had no effect on dispersion during control conditions. The increased APD dispersion during hypokalemic ischemia is considered a major arrhythmic substrate and only ZP123 prevented the increase in APD dispersion. In conclusion, ZP123 is a new potent AAP analog with improved stability.
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In spite of many years of research and the availability of a wide selection of antiarrhythmic drugs, ventricular tachyarrhythmias (VTs) are still a major clinical problem and one of the leading causes of death in the Western world. Especially the attempts to prevent VT by pharmacological intervention in patients recovering from myocardial infarction have been disappointing. In this patient group, most antiarrhythmic drugs are at best without impact on overall mortality (Naccarelli et al., 2000) , whereas others may even increase mortality due to their proarrhythmic potential (Echt et al., 1991; Waldo et al., 1996) . Only a few antiarrhythmic drugs have been shown to actually increase long-term survival in these patients (Hjalmarson, 1984; ISIS-1, 1986) . Thus, there is still a great need for new, safe, and effective antiarrhythmic drugs.
A group of peptides with antiarrhythmic properties [named the antiarrhythmic peptides (AAPs)] were discovered in the early eighties (Aonuma et al., 1980 ). The endogenous AAP (H-Gly-Pro-4Hyp-Gly-Ala-Gly-OH) was first isolated from bovine atria and was found to synchronize spontaneous automaticity of isolated cardiac myocytes (Aonuma et al., 1982) . Later, several synthetic derivatives of AAP have been synthesized and tested for antiarrhythmic efficacy in vivo and in vitro (Kohama et al., 1987; Dikshit et al., 1988; Kohama et al., 1988; Dhein et al., 1994) . Among these, H-GlyAla-Gly-4Hyp-Pro-Tyr-NH 2 (AAP10) is one of the most potent and also the most thoroughly investigated (Dhein et al., 1994) . Double cell voltage-clamp studies have shown that AAP10 increases gap junction intercellular communication (GJIC) in the absence of changes in membrane conductance or basal current (Muller et al., 1997a,b) . AAPs have been shown to reduce the increased dispersion of action potential duration during regional ischemia in isolated rabbit hearts without effects on effective refractory period (ERP) or action potential duration and shape (Dhein et al., 1994; Kjølbye et al., 2002) . In addition, in vivo studies in rodents have demonstrated that AAPs may antagonize CaCl 2 -, ouabain-, and aconitine-induced arrhythmias (Ronsberg et al., 1986; Kohama et al., 1987 Kohama et al., , 1988 .
By selectively acting on GJIC, the AAPs distinguish themselves from most antiarrhythmic drugs that affect ion channels. Considering that the proarrhythmic potential of most antiarrhythmic drugs are linked to their ion channel-modulating effect, the fact that the AAPs presumably lack effects on ion channels makes these compounds interesting as new potentially safer antiarrhythmic drugs. In addition, the role for GJIC in the mechanism of arrhythmias has been increasingly recognized in recent years. However, the therapeutic potential of the AAPs has been hampered by their poor enzymatic stability. Therefore, we developed a new AAP analog called Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH 2 (ZP123) that, as AAP10, increases GJIC in adult cardiomyocytes (Xing et al., 2003) . ZP123 is structurally closely related to AAP10; however, all L-amino acids have been substituted with D-isomers, which are expected to protect against enzymatic degradation and thereby increase the stability of the peptide. In this study, we examined the hypothesis that ZP123 has increased in vitro stability and a prolonged halflife in vivo relative to AAP10. We also investigated whether the chemical modification of the peptide changed the pharmacodynamic effects of ZP123 by comparing the electrophysiological properties of ZP123 and AAP10 in an in vivo model of second degree AV-block and in the isolated rabbit heart.
Materials and Methods
All experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health.
Drugs
ZP123 as well as the trifluoroacetic acid salt of AAP10 and internal standard [Gly 4, 6 (1,2-di 13 C-15 N)-labeled ZP123] were synthesized in-house by standard solid-phase F-moc chemistry. The compounds were identified by mass spectrometry and the purity, determined by RP-HPLC, was determined to be 99, 97, and 99%, respectively.
In Vitro Stability of ZP123 and AAP10 in Rat and Human Plasma
Study Design. One hundred microliters of ZP123 or AAP10 (2 mM in water) was mixed with 900 l of lithium heparin-stabilized rat plasma or human plasma in triplicate at t ϭ 0 and incubated at 37°C under sterile conditions. Then 100 l of the drug-plasma mixture was removed at appropriate intervals based on expected halflives and degradation was stopped by precipitation of the sample with 10 l of MeCN/trifluoroacetic acid (50:50 v/v). The sampling intervals used for ZP123 were 0.1 min, 6 h 30 min, 22 h 50 min, 31 h 5 min, 46 h 40 min, 54 h, 70 h 42 min, 78 h 22 min, and 166 h 47 min, whereas the intervals used for AAP10 were 0.1, 1, 2, 3, 5, 7, 10, 15, and 20 min. A control plasma sample without the drug but treated in the same manner was also analyzed. The precipitated plasma samples were centrifuged for 15 min at 12,000 rpm at ambient temperature. The concentration of ZP123 or AAP10 was determined by RP-HPLC analysis of the resulting supernatant.
HPLC Analysis. Samples containing ZP123 and AAP10 were analyzed by RP-HPLC method 1 and 2 (Table 1) , respectively, using 10-l injections.
Half-lives (t 1/2 ) for the test compounds in plasma solutions were calculated from plots of the natural logarithm of the residual concentration (peak heights) against time using the formula t 1/2 ϭ 1/k obs ⅐ ln(2), where k obs is the apparent first order rate constant for the observed degradation.
Pharmacokinetics of ZP123 and AAP10 after i.v. Infusion in Conscious Rats. Sixteen male Sprague-Dawley rats (324 -413 g) from M&B (Ll. Skenued, Denmark) were anesthetized with an s.c. injection of Hypnorm-midazolam solution (0.2 ml/100 g). The neurolept anesthetic solution was prepared by mixing one part of Hypnorm (0.315 mg/ml fentanyl citrate and 10 mg/ml fluanisone) (Janssen Pharmaceuticals, Antwerp, Belgium) with two parts of distilled water and one part of midazolam (5 mg/ml) (Dumex-Alpharma, Copenhagen, Denmark). Catheters were inserted into the femoral vein and artery. After surgery, the rats were allowed to recover for 5 days before drug administration was initiated. For the first experiment (n ϭ 8), ZP123 and AAP10 were dissolved in phosphate-buffered saline (pH 7.4), mixed, and coadministered by i.v. infusion at a rate of 25 l/min/rat for 30 min. The average infusion rates of ZP123 and AAP10 were 8.8 and 4.4 nmol/min/kg, respectively. Before the experiment, the animals received an i.v. bolus dose of 500 IU of heparin. The first blood sample was obtained from the artery catheter 10 min before infusion start and the following samples were obtained at t ϭ 15/29 (just before infusion stop), 32, 35, 40, 45, 55, 70, 90, 120, 150, and, 180 min. Blood samples were immediately transferred to ice-chilled EDTA-coated microcentrifuge tubes containing 30 l of protease inhibitor cocktail (Complete, 1 tablet in 2 ml of water; Roche Diagnostics, Mannheim, Germany). The tubes were stored on ice until centrifugation at 4°C for 5 min (10,000g). The plasma (150 -250 l) was collected and stored at Ϫ20°C until analysis.
In the second experiment (n ϭ 7), AAP10 dissolved in phosphatebuffered saline (pH 7.4) was infused at a dose of 48 nmol/min/kg for 5 min, blood samples were obtained at 3 and 5 min, and treated as described above.
Quantification of ZP123 and AAP10 in Rat Plasma
The plasma samples were thawed on ice, and 170 l of plasma was diluted to 800 l by addition of a solution containing internal standard (IS) (100 nM) and 4% (w/v) sucrose in water. For samples containing less than 170 l of plasma, the missing volume was replaced with 4% (w/v) sucrose in water.
AAP10, ZP123, and the IS were extracted on Waters Oasis HLB solid phase extraction columns (1 ml, 30 mg of resin). Samples (600 l) were added to the SPE columns preconditioned with MeOH and water (1 ml of each). The columns were washed with 2% (w/v) sucrose followed by water (1 ml of each), and finally the analytes were eluted with 1 ml of 30% (v/v) MeOH in water. After elution, samples were evaporated to dryness and reconstituted in 60 l of LC/MS/MS solvent A (Table 1 ). The extracted samples (40 l) were analyzed by LC/MS/MS using the conditions described in Table 1 . The plasma concentration of ZP123 and AAP10 was quantified using an external standard curve (0.5-500 nM, n ϭ 7) extracted from spiked blank rat plasma treated in the same manner as the unknown samples. The correlation between log response (peak area ϫ (IS concentration/IS peak area)) and log concentration was linear (R 2 Ն 0.995) for both compounds. The lower limit of detection of ZP123 and AAP10 was 0.70 and 2.6 nM, respectively. All LC/MS/MS settings, integration, and calculations were controlled by Masslynx software, version 3.5 (Manchester, UK).
Pharmacokinetic Calculations. Data were fitted to a two-compartment open model with zero order input (eq.1) using the NelderMead simplex algorithm. The weighting exponent () was based on a graphical estimation of the error distribution in the data sets estimated from the slope (0.9) of the ln ((C obs Ϫ Ĉ OLS )
2 ) versus ln (Ĉ OLS ) plot (Gabrielson and Weiner, 2000) . The final fitting was performed using 1/Ĉ as weighting function. Analysis of the standard residuals ((C obs ϪĈ )/SE(Ĉ )) versus time plots of the individual fits indicated the sample point at t ϭ 32 min was associated with a high degree of uncertainty in five of the eight rats. The removal of this particular time point in these rats significantly improved the fits based on sum of squared residuals (p Ͻ 0.05, F test). The data fitting sessions were performed in WinNonlin 3.1 (Pharsight, Mountain View, CA), and estimation of error distribution was performed using Excel 97-SR2 (Microsoft, Redmond, WA). The body clearance of AAP10 was estimated from eq. 2 assuming steady-state plasma concentration.
where
t i ϭ the length of infusion, t* ϭ t Ϫ t i , for t Ͼ t i , and t* ϭ 0, for t Յ t i . D ϭ dose, k 21 ϭ tractional rate constant from the peripheral compartment to the central compartment.
where R in is the infusion rate and C ss is the plasma concentration in steady state.
Effect of ZP123 and AAP10 on Ouabain-Induced Second Degree AV-Block in Anesthetized Mice
One hundred male NMRI mice (25-30 g) from Bomholdtgaard (Skendsved, Denmark) were anesthetized by an s.c. injection of 50 to 75 l/10 g of mouse Hypnorm-midazolam solution. An i.v. cannula was inserted into the tail vein for i.v. administration of ouabain, and another i.v. cannula was inserted for i.v. administration of vehicle, ZP123, or AAP10 (10 Ϫ12 -10 Ϫ6 mol/kg i.v., n ϭ 4 -12/dose level). The lead II ECG signal was recorded continuously by positioning of stainless steel ECG electrodes on the right forelimb and on the left hind limb. The ground electrode was placed on the right hind limb. The signal was amplified (5,000 -10,000ϫ) and filtered (0.1-150 Hz) via a Hugo Sachs Electronik model 689 ECG module (Harvard Apparatus GmbH, March-Hugstetten, Germany). The analog signal was digitized via a 12-bit data acquisition board and sampled at 1,000 Hz using the Notocord HEM 3.1 software for Windows NT (Notocord Systems SA, Croissy-sur-Seine, France).
After a 10-min equilibration period, the test sample of drug was injected into the tail vein and 3 min later i.v. infusion of ouabain (4 mg/kg/min, ouabain; Sigma-Aldrich, Vallensbaek, Denmark) was started. Mice pretreated with vehicle (isotonic saline) were tested on all days of the experiment as a measure of the control level in untreated animals. Injection volume was 100 l in all experiments. The time lag to onset of AV-nodal conduction block was determined as the time from the start of ouabain infusion until the first second degree AV-block. To examine the effect of test compounds on ouabain-induced changes in RR, PQ, QRS, QT interval, and T-wave height, these ECG parameters were recorded at 0, 60, 120, and 180 s after start of ouabain infusion. Eventually, mice developed ventricular fibrillation after about 5 min of ouabain infusion; this time lag was also recorded.
Effects of ZP123 and AAP10 in the Isolated Rabbit Heart
Anesthesia and Surgery. Male Ssc:CPH rabbits (2.5-4.0 kg) from Hvidesten (Allerød, Denmark) were anesthetized with Hypnorm-Dormicum, heparinized, tracheotomized, and ventilated as described previously (Kjølbye et al., 2002) . The abdominal and thoracic cavities were opened, the ascending aorta was exposed and cannulated, and the heart was excised and transferred to the perfusion apparatus as described previously (the only deviation from referenced method being that the heart was not cooled with cold KrebsHenseleit before cannulation) (Kjølbye et al., 2002) .
Preparation for Electrophysiological and Hemodynamic Recordings. After transfer to the perfusion apparatus, ECG elecIn Vivo and in Vitro Studies of the New AAP Analog ZP123 1193 at ASPET Journals on January 7, 2018 jpet.aspetjournals.org trodes were positioned and a fluid-filled balloon was inserted into the left ventricle for measurements of left ventricular pressure (LVP) (Kjølbye et al., 2002) . The volume of the balloon was adjusted to give an end-diastolic pressure of 5 to 8 mm Hg. Eight monophasic action potential (MAP) electrodes were placed on the epicardial surface of the heart, three on the right ventricle and five on the left. When all electrodes were in place, the water bath was elevated to ensure that the heart was immersed in 38°C Krebs-Henseleit solution at all times.
Perfusion Technique and Perfusion Media. The hearts were perfused with a filtered, prewarmed (38°C) Krebs-Henseleit solution bobbled with 95% O 2 , 5% CO 2 with the following composition: 118.0 mmol/l NaCl, 4.7 mmol/l KCl, 2.5 mmol/l CaCl 2 ⅐ 2H 2 O, 1.2 mmol/l KH 2 PO 4 , 1.6 mmol/l Mg 2 SO 4 ⅐ 7H 2 O, 2.0 mmol/l sodium pyruvate, 24.9 mmol/l NaHCO 3 , and 5.6 mmol/l glucose) in the Langendorff mode at constant perfusion pressure (60 mm Hg) (Kjølbye et al., 2002) .
Study Design of Isolated Heart Experiments. The time schedule for the experiment was as follows:
1. Fifteen minutes of perfusion with normal Krebs-Henseleit (control period). 2. Fifteen minutes of perfusion with vehicle, 0.1 nM ZP123, or 0.1 nM AAP10 added to normal Krebs-Henseleit (normokalemic treatment period). 3. Fifteen minutes of perfusion with vehicle, 0.1 nM ZP123, or 0.1 nM AAP10 added to Krebs-Henseleit solution containing a reduced K ϩ concentration (2.5 mM) (hypokalemic treatment period). 4. Induction of regional ischemia followed by 30 min of perfusion with vehicle, 0.1 nM ZP123, or 0.1 nM AAP10 added to KrebsHenseleit solution containing a reduced K ϩ concentration (2.5 mM) (hypokalemic ischemic treatment period).
Induction of Regional Ischemia. Before the beginning of the experiment a ligature was placed around a major branch of the circumflex artery supplying a large part of the left ventricle. Both ends of the ligature were passed through a small plastic tube enabling induction of ischemia by pressing the plastic tube against the heart and clamping the ends of the ligature.
Effective Refractory Period. The effective refractory period (ERP) was measured in the border zone of the infarction at the end of the hypokalemic ischemic treatment period by programmed electrical stimulation, using square wave impulses of 2-ms duration at twice diastolic threshold (coaxial stimulation electrode and stimulator type 215/I Hugo Sachs Elektronik; Harvard Apparatus GmbH, March-Hugstetten, Germany). The left ventricle was paced at a basic cycle length of 300 ms. For every 10th impulse, an extra-stimulus was superimposed with a delay of 90 ms. The delay was increased in steps of 5 ms until the extra-stimulus elicited a response. ERP was defined as the longest delay period that failed to elicit a response.
Area at Risk of Infarction. At the end of the experiment the hearts were perfused with Evans blue dye to evaluate the area at risk of infarction as described previously (Kjølbye et al., 2002) .
Recordings and Measurements. Coronary flow, LVP, perfusion pressure, lead I of the ECG, and eight MAP recordings were continuously recorded. The ECG and MAPs were sampled at 2,000 Hz, and the pressure and flow parameters at 500 Hz. The output was analyzed using the Notocord HEM version 3.3 software (Notocord Systems SA). From these recordings, the following electrophysiological parameters were measured: average APD 90 , APD 90 dispersion, average APD 70 , APD 70 dispersion, and dispersion of time for MAP dV/dt max.
A total of all eight MAP recordings as well as a selective measure of the five MAP recordings on the left ventricle were calculated. The parameters were measured during stable conditions on 20 consecutive complexes at the end of each of the four periods. Average APD 90/70 was calculated for each complex as the average duration from dV/dt max to 90 and 70% repolarization of the MAP measurements, and an average of the 20 complexes was calculated. Likewise, the dispersion was calculated for each complex as the standard deviation of the APD measurements, and an average of the 20 complexes was calculated. Dispersion of time for dV/dt max was measured as the time lag between the earliest and latest dV/dt max of the eight MAP recordings. In addition, heart rate derived from LVP, LVP dP/dt max, and mean coronary flow was calculated as an average of measurements from 10 s at the end of each period starting from the time of measurement of the electrophysiological parameters.
Statistics
Two-way classified data were analyzed for interaction and main effects (time and group) using a two-way analysis of variance for repeated measures, and one-way classified data were analyzed for main effect using a one-way analysis of variance. When overall differences were detected, a post hoc analysis was performed using Fisher's least significant difference test. When multiple one-way analyses of variance were performed at different time periods among the same groups, the level of significance was reduced in accordance with Bonferroni's rule of correction for multiple comparisons. Differences were considered significant at the 0.05 level. All data are mean Ϯ S.E.M.
Results

In Vitro Stability of ZP123 and AAP10 in Rat and Human Plasma
The t 1/2 of ZP123 in rat and human plasma was 10.3 Ϯ 1.3 and 14.0 Ϯ 1.5 days, whereas t 1/2 for AAP10 in rat and human plasma was 3.8 Ϯ 0.1 and 11.8 Ϯ 1.0 min, respectively.
Pharmacokinetics of ZP123 and AAP10 after i.v. Infusion in Conscious Rats
The plasma concentration versus time profile of ZP123 after 30 min i.v. infusion based on the estimated mean pharmacokinetic parameters and the obtained plasma concentrations are illustrated in Fig. 1 . Just before the infusion stop (29 min), the plasma concentration reached 618 Ϯ 18 nM. After infusion stop, ZP123 was rapidly distributed causing a rapid drop in plasma concentration until it entered the elimination phase approx. 20 min after infusion stop. (Table 2) , the open circles represent the mean plasma concentrations from all rats (n ϭ 8), and the error bars indicate the standard deviation.
The central (V c ) and the steady state (V ss ) distribution volumes were estimated to approx. 10 and 20% (v/w), respectively. The clearance of ZP123 was found to be 12 ml/kg/min and the terminal half-life was 16 min. A summary of selected pharmacokinetic parameters is listed in Table 2. AAP10 was not detected after 30-min infusion at a rate of 4.4 nmol/min/kg. Using the limit of detection of 2.6 nM as the maximum plasma concentration and assuming steady state within the 30-min infusion period, the clearance was estimated to be 1,700 ml/min/kg using eq. 2. The detection of AAP10 in plasma was only possible after infusion of 48 nmol/ min/kg, which resulted in mean plasma concentrations of 16 Ϯ 1.7 and 21 Ϯ 1.9 nM after infusion for 3 and 5 min, respectively. There was no significant difference between the values obtained at 3 and 5 min (p Ͼ 0.05, paired t test), suggesting that steady state was reached already at this point. The clearance calculated from the plasma concentration obtained at 5 min, assuming steady state, was 2,300 ml/min/kg.
Effect of ZP123 and AAP10 on Ouabain-Induced Second Degree AV-Block in Anesthetized Mice
Intravenous infusion of ouabain (4 mg/kg/min) produced second degree AV-block (as illustrated on the ECG tracing in Fig. 2) after about 2 min. ZP123 and AAP10 prolonged the time lag until ouabain-induced AV-block dose dependently at doses from 10 Ϫ11 to 10 Ϫ7 (ZP123) and 10 Ϫ11 to 10 Ϫ6 (AAP10) mol/kg i.v. (Fig. 3A) . Maximal efficacy of ZP123 was reached at a 10-fold lower dose (10 Ϫ8 mol/kg i.v.) than for AAP10 (10 Ϫ7 mol/kg i.v.). Both compounds showed a bell-shaped dose-response relationship with a reduced (AAP10) or no (ZP123) effect at the highest dose (Fig. 3A) .
Ouabain produced an increase in RR, PQ, QRS, and QT intervals and an accentuated negative T-wave with a striking resemblance to the Cohn effect seen in humans during digoxin intoxication (Fig. 2) . However, neither ZP123 nor AAP10 affected any of the measured EEG intervals or Twave morphology significantly relative to responses obtained in vehicle-treated mice (data not shown).
After about 5 min of ouabain infusion, the mice developed ventricular fibrillation, which terminated the experiment. ZP123 significantly delayed the onset of ventricular fibrillation at 10 Ϫ9 and 10 Ϫ7 mol/kg i.v., and AAP10 significantly delayed the onset at 10 Ϫ9 , 10 Ϫ7 , and 10 Ϫ6 mol/kg i.v. However, these effects seem to be random because there was no clear dose-response relationship (Fig. 3B) .
Effects of ZP123 and AAP10 in the Isolated Rabbit Heart
Area at Risk. The average area at risk of infarction was similar in all groups with an average size of 44 Ϯ 1% of the left ventricular mass. Hemodynamics. There was no significant overall difference in heart rate among groups (Table 3) . Hypokalemic ischemia produced a similar and significant decrease in LVP dP/dt max and mean coronary flow in all groups (Table 3) .
Action Potential Duration and ERP. There was no difference among groups in ERP or average APD 90/70 (Table  3) .
Dispersion of APD. During hypokalemic ischemia, the total dispersion of APD 90 and APD 70 increased significantly relative to the level at control in the vehicle and AAP10-treated group, whereas there was only a slight and insignificant increase in the ZP123-treated group (Figs. 4A and 5A ). On the left ventricle, the dispersion increased significantly during hypokalemic ischemia relative to the control-level in all groups (Figs. 4B and 5B). During hypokalemic ischemia, the total and left APD 90 and total APD 70 dispersion was significantly lower in the ZP123-treated group than in the vehicle group. Thus, ZP123 but not AAP10 prevented the increased dispersion caused by hypokalemic ischemia. The dispersion during normokalemic treatment was similar to the level during control in all groups, and there was no difference among groups in this period.
Dispersion of Time for dV/dt max. During hypokalemic ischemia the dispersion of time for dV/dt max increased significantly in the vehicle-and AAP10-treated group relative to the level during control. However, 0.1 nM ZP123 completely prevented the ischemia-induced increase in dispersion. During hypokalemic ischemia the ZP123 group was significantly different from the vehicle as well as the AAP10-treated group (Fig. 6) .
Discussion
The present study showed that ZP123 is superior to AAP10 in terms of in vitro and in vivo stability. Thus, the in vitro half-life of ZP123 in plasma was more than 10 days compared with less than 15 min for AAP10. This result is not unexpected, because AAP10 consists of L-amino acids that easily undergo proteolysis, whereas the substitution for D-amino acids in ZP123 protects against enzymatic degradation.
Due to the ultrarapid elimination of AAP10, it was not possible to perform a full pharmacokinetic characterization of AAP10. The pharmacokinetic characterization based on 30-min infusion of ZP123 showed that the plasma concentration reached approx. 80% of the C ss (using eq. 2) and declined in a biphasic manner after infusion stop. The V ss of 20% (v/w) correlates to the volume of extra cellular water, whereas the V c corresponded to the distribution volume of drugs highly bound to albumin in the plasma compartment (Rowland and Tozer, 1989) .
In the first experiment, AAP10 could not be detected and based on that, total body clearance of AAP10 was estimated to be at least 1,700 ml/min/kg. In the second experiment, AAP10 was measured in plasma after infusion with a very high dose of AAP10 (48 nmol/min/kg) for 5 min, and clearance was estimated to be about 2,300 ml/min/kg. Thus, total body clearance of AAP10 was at least 140 to 190 times faster than the body clearance of ZP123, confirming that ZP123 was far more stable than AAP10 in vivo as well as in vitro.
In a murine in vivo model of ouabain-induced second degree AV-block the ZP123 dose that elicited maximal effect was 10-fold lower than the AAP10 dose eliciting maximal TABLE 3 Hemodynamic and electrophysiological parameters in the isolated perfused rabbit heart
Values are means
Vehicle (n ϭ 12) effect, suggesting that ZP123 is more potent than AAP10 in this in vivo model. The rationale for using this model is that ouabain-infusion leads to high intracellular calcium levels that in turn causes uncoupling of gap junction channels and slowed conduction that may ultimately result in conduction block. Thus, the delay in time to second degree AV-block was used as an indirect measure of prevention of Ca 2ϩ -induced uncoupling of gap junction channels and slowed conduction. Both compounds had a bell-shaped dose-response relationship with a supramaximal dose range. We have observed similar bell-shaped dose-response curves for AAP10, ZP123, sotalol, amiodarone, and verapamil during CaCl 2 -induced second degree AV-block in mice (our unpublished observations), suggesting that the bell-shaped dose-response curve may be a characteristic finding of high calcium-associated AV-block in mice. Although bell-shaped dose-response curves are common in excitatory tissue, the exact mechanism responsible for this phenomenon during ouabain and CaCl 2 -induced AV-block is unknown.
Neither AAP10 nor ZP123 affected the ouabain-induced increase in RR, PQ, QT, or QRS interval duration. Theoretically, a compound that increases GJIC and thereby increases conduction velocity would be expected to reduce ouabain-induced prolongation of PR and QRS intervals. The reason for lack of effect on ECG intervals in the present study is unknown but may be related to the difficulty in obtaining accurate measurements of ECG intervals in mice.
ZP123 and AAP10 failed to dose dependently prevent VF in this model. Whereas increased GJIC may be expected to reduce the incidence of VF caused by reentry (i.e., by preventing slowed conductance and unidirectional conduction block), it may have little or no effect on VF caused by focal jpet.aspetjournals.org Downloaded from mechanisms (i.e., increased automaticity and/or triggered activity). Because ouabain-infusion produces high intracellular calcium levels, triggered activity is the likely mechanism involved in VF in this model. In addition, reentrant VF is difficult to initiate and sustain in mice due to the small size of the heart. Therefore, assuming that ouabain-induced VF is caused by a focal mechanism, the lack of a clear effect of ZP123 and AAP10 on VF in this model may not be surprising.
In the isolated perfused rabbit heart, 0.1 nM AAP10 failed to show any effects, whereas 0.1 nM ZP123 significantly prevented the increase in dispersion of action potential duration and onset during hypokalemic ischemia. The compounds were only tested at one concentration, and therefore it cannot be ruled out that AAP10 may be effective at other concentrations. The relatively low concentration of 0.1 nM was chosen based on previous work showing effect of 0.1 nM of the synthetic AAP-analog HP-5 on APD dispersion in a similar model (Kjølbye et al., 2002) . Moreover, previous studies demonstrated that 0.1 nM AAP10 reduced the dispersion of activation-recovery intervals in isolated perfused normal rabbit hearts (Dhein et al., 1994) . Interestingly, the same group demonstrated a 100-fold increased sensitivity of AAP10 in guinea pig papillary muscles during hypoxia (Muller et al., 1997b) . Considering that maximal effect of AAP10 was achieved at 10 nM during normal conditions (Dhein et al., 1994) , and cardiac sensitivity to AAP10 is increased a 100-fold during hypoxia, 0.1 nM AAP10 was chosen for the present study.
The lack of effect of AAP10 on APD dispersion after 30 min of ischemia is in accordance with previous findings. In rabbit hearts, 10 nM AAP10 reduced the activation-recovery intervals only within the first couple of minutes after induction of regional ischemia, whereas there was no effect after 30 min (Dhein et al., 1994) . Thus, present and previous findings consistently show a weak effect of AAP10 on dispersion during ischemia. This suggests that ZP123 reduces dispersion of action potential duration more effectively than AAP10 during regional ischemia.
Increased dispersion of action potential duration is believed to facilitate the induction of reentry VT by increasing the likelihood of unidirectional block. Therefore, by reducing dispersion, ZP123 may protect against reentry VT during myocardial ischemia. This hypothesis was confirmed in a recent study of VT inducibility in open-chest dogs 1 to 4 h after ligation of the left descending artery. The study showed that 1 to 70 nM ZP123 prevents unidirectional block and protects against reentry VT induced by programmed electrical stimulation (Xing et al., 2003) .
ZP123 and AAP10 had no effect on average APD 90 , average APD 70 , ERP, area at risk, or hemodynamic parameters at any point throughout the experiment. These observations are in accordance with previous findings for these compounds and for the endogenous antiarrhythmic peptide AAP and the synthetic derivative HP-5 (Argentieri et al., 1989; Dhein et al., 1994; Kjølbye et al., 2002; Xing et al., 2003) . In isolated rabbit hearts subjected to hypokalemic ischemia-reperfusion, 0.1 nM HP-5 significantly reduced dispersion of APD 90 without affecting average APD, heart rate, contractility, or coronary flow (Kjølbye et al., 2002) . In isolated canine Purkinje fibers, it was shown that AAP did not affect inotropy or any of the electrophysiological parameters measured (maximum diastolic potential, action potential amplitude, maximum rate of depolarization, and action potential duration at 50 and 95% repolarization) (Argentieri et al., 1989) . In the isolated rabbit heart, AAP10 had no effect on mean action potential duration, left ventricular end-diastolic pressure, coronary flow, QRS duration, or on the PQ interval (Dhein et al., 1994) . In addition, AAP10 did not affect the action potential in isolated papillary muscles from guinea pig hearts in concentrations up to 1 M (Dhein et al., 1994) . Thus, there is a large body of evidence supporting the hypothesis that the AAPs selectively increase GJIC and reduces dispersion without affecting transmembrane ion currents.
In summary, the present study showed that the new AAP analog ZP123 reduced MAP heterogeneity during hypokalemic ischemia at a concentration where AAP10 was without effect. Moreover, ZP123 was more potent than AAP10 in protecting against ouabain-induced second degree AV-block. The increased potency of ZP123 in vivo may be related to increased resistance to enzymatic degradation relative to AAP10, enabling sufficient plasma levels of active compound at the time of ouabain-infusion. However, the increased enzymatic stability cannot explain the difference in effects of the two compounds seen in the isolated heart experiments because perfusion in the Langendorff mode ensures a stable and constant delivery of compound. Thus, in addition to enhancing stability, the chemical modification of ZP123 may in itself by an unknown mechanism increase potency.
The potential clinical use of the AAPs have previously been hampered by their poor enzymatic stability and very short half-life, but with the development of this novel stable AAP analog, the therapeutic potential of antiarrhythmic peptides can be investigated in vivo.
